elinogrel
Small moleculeexperimental
Elinogrel (INN, USAN) was an experimental antiplatelet drug acting as a P2Y12 inhibitor. Similarly to ticagrelor and in contrast to clopidogrel, elinogrel was a reversible inhibitor that acted fast and short (for about 12 hours), and it was not a prodrug but pharmacologically active itself. The substance was used in form of its potassium salt, intravenously for acute treatment and orally for long-term treatment. Development was terminated in 2012. — Wikipedia
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2007 (NCT00546260)
Timeline
Indications
Mechanism of action
- Purinergic receptor P2Y12ANTAGONIST
P2RY12 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F- Mol. weight
- 523.96 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaElinogrel ↗
- ChEMBLCHEMBL2103828 ↗
Also known as
- elinogrel
- elinogrel
- elinogrel
- elinogrel
- prt060128
- prt060128
- prt060128
- prt 060128
- prt-060128
- prt-060128
- prt-060128
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00984113 | Phase 1 | Sep 1, 2009 | Novartis, Portola Pharmaceuticals |
| NCT00751231 | Phase 2 | Dec 1, 2008 | Duke University, Portola Pharmaceuticals, University of Alberta |
| NCT00546260 | Phase 2 | Nov 1, 2007 | Duke University, Portola Pharmaceuticals |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Portola Pharmaceuticals | For profit | 3 | 3 | 2 | 2007 |
| Duke University | Academic/Hospital | 2 | 0 | 1 | 2007 |
| Novartis | For profit | 1 | 0 | 1 | 2009 |
| University of Alberta | Academic/Hospital | 1 | 0 | 1 | 2008 |
4 organizations
Page 1 / 1